American Society of Clinical Oncology

SHERPA: White

People

  1. Mauro
    Mauro
  2. Scheinberg
    Scheinberg
  3. Berman
    Berman
  4. Levine
    Levine
  5. Park
    Park
  6. Sadelain
    Sadelain
  7. Stein
    Stein
  8. Rampal
    Rampal
  9. Wang
    Wang
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Adult Leukemia (209)
  2. Center for Hematologic Malignancies (209)
  3. Department of Medicine (208)
  4. Hematologic Malignancies, Division of (207)
  5. GSK Faculty (72)
  6. Hematologic Malignancies Research (46)
  7. Sloan Kettering Institute Faculty (46)
  8. Molecular Pharmacology and Chemistry Program Faculty (43)
  9. Tow Center for Developmental Oncology (TCDO) (38)
  10. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (24)
Search Within
  1. "Adult Leukemia"
Formats
  1. Meeting Abstract (148)
  2. Journal Article (56)
  3. Editorial (3)
  4. Correspondence (1)
  5. Review (1)
Groups
  1. Adult Leukemia (209)
  2. Center for Hematologic Malignancies (209)
  3. Department of Medicine (208)
  4. Hematologic Malignancies, Division of (207)
  5. GSK Faculty (72)
  6. Hematologic Malignancies Research (46)

More Groups

People
  1. Martin Tallman (40)
  2. Jae Park (27)
  3. Renier Brentjens (26)
  4. Eytan Stein (24)
  5. David Scheinberg (21)
  6. Michael Mauro (21)

More People

Years
  1. 2024 (1)
  2. 2023 (15)
  3. 2022 (15)
  4. 2021 (9)
  5. 2020 (13)
  6. 2019 (13)

More Years

Publications
  1. Journal of Clinical Oncology (199)
  2. American Society of Clinical Oncology Educational Book (4)
  3. JCO Precision Oncology (3)
  4. Journal of Oncology Practice (3)

Results (209)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CML and the WHO: Why?
    Editorial

    Berman, E.; Shah, N. P.; Deninger, M.; Altman, J. K.; Amaya, M.; Begna, K.; Bhatia, R.; Chan, O.; Collins, R.; Curtin, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • MANIFEST: Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naive myelofibrosis
    Journal Article

    Mascarenhas, J.; Kremyanskaya, M.; Patriarca, A.; Palandri, F.; Devos, T.; Passamonti, F.; Rampal, R. K.; Mead, A. J.; Hobbs, G.; Scandura, J. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)
    Meeting Abstract

    Atallah, E. L.; Mauro, M. J.; Sasaki, K.; Levy, M. Y.; Koller, P. B.; Sadek, I.; Yang, D.; Ruckel-Kumar, J.; Khan, M. H.; Cortes, J. E.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML)
    Meeting Abstract

    Smith, C. C.; Vachhani, P.; Garcia-Manero, G.; Grieselhuber, N. R.; Guru Murthy, G. S.; Bhatia, A.; Arora, J.; Izadi, H.; Fiorino, A.; Rampal, R.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Meeting Abstract

    Bewersdorf, J. P.; Verstovsek, S.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E. M.; Mauro, M. J.; Rampal, R.; Bose, P.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Implementing a germline testing program using fingernail specimens for patients with hematologic malignancies and initial clinical findings
    Meeting Abstract

    Walsh, M. F.; Fiala, E.; Birsoy, O.; Haque, T.; Stein, E. M.; Shukla, N.; Sulis, M. L.; Goldberg, A. D.; Rana, S.; Khurram, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clonal hematopoiesis in survivors of childhood cancer
    Meeting Abstract

    Friedman, D. N.; Chan, I. C. C.; Moskowitz, C. S.; Li, S.; Turner, K.; Liu, J.; Bouvier, N.; Walsh, M. F.; Spitzer, B.; Kung, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a real-world setting
    Meeting Abstract

    Moslehi, J. J.; Aras, M. A.; Oehler, V. G.; Thompson, J. E.; McCloskey, J. K.; Heinrich, M. C.; DeGutis, I. S.; Fish, S. M.; Mauro, M. J.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pelabresib (CPI-0610) monotherapy in high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: Preliminary results from MANIFEST study
    Meeting Abstract

    Passamonti, F.; Patriarca, A.; Knapper, S.; Rivera, C.; Scandura, J.; Devos, T.; Granacher, N.; Mead, A. J.; Oh, S.; Palmer, J. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3
    Meeting Abstract

    Shah, B. D.; Cassaday, R. D.; Park, J. H.; Houot, R.; Oluwole, O. O.; Logan, A.; Boissel, N.; Leguay, T.; Bishop, M. R.; Topp, M. S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save